Nu-Med Plus Remains Revenue-Less, Files 10-Q as Development Stage Firm

TL;DR

**NUMD is a pre-revenue medical device long shot; avoid unless you're a high-risk speculator.**

AI Summary

Nu-Med Plus, Inc. (NUMD) reported no revenue for the quarter ended June 30, 2025, consistent with its status as a development-stage company focused on medical device technology. The company's net loss for the three months ended June 30, 2025, was not explicitly stated in the provided excerpt, but its operational status suggests ongoing losses. Key business changes include its continued operation as a smaller reporting company and non-accelerated filer, indicating limited financial scale and market capitalization. The primary risk remains the lack of revenue generation and the inherent challenges of bringing medical devices to market, requiring significant capital and regulatory approvals. Strategically, Nu-Med Plus is focused on its core business in surgical and medical instruments, as evidenced by its SIC code 3841. The company confirmed it has filed all required reports under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months.

Why It Matters

For investors, Nu-Med Plus's continued lack of revenue signals high risk and a long path to profitability, making it a speculative investment. Employees face uncertainty given the company's development stage and reliance on future product commercialization. Customers are not yet impacted as the company is not generating sales from its medical devices. The broader market sees this as a typical profile for a micro-cap medical device developer, highlighting the competitive pressures and capital intensity in the surgical and medical instruments sector.

Risk Assessment

Risk Level: high — The risk level is high because Nu-Med Plus, Inc. reported no revenue for the quarter ended June 30, 2025, indicating it is a development-stage company with no current income stream. This lack of revenue, combined with its classification as a 'smaller reporting company' and 'non-accelerated filer,' suggests limited financial resources and significant operational hurdles to achieve commercial viability.

Analyst Insight

Investors should approach Nu-Med Plus (NUMD) with extreme caution, recognizing it as a highly speculative investment. Due to the absence of revenue and its development-stage status, investors should only consider a position if they have a high-risk tolerance and a long-term horizon, understanding that significant capital is required for medical device commercialization.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (Nu-Med Plus, Inc. reported no revenue for the quarter ended June 30, 2025, indicating its development-stage status.)
• 10-Q — Form Type (The company filed a Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934.)
• 20250630 — Conformed Period of Report (This date signifies the end of the financial period covered by the 10-Q filing.)
• 20250811 — Filed As Of Date (This is the official date the 10-Q was filed with the SEC.)

Key Players & Entities

• Nu-Med Plus, Inc. (company) — registrant filing the 10-Q
• SEC (regulator) — recipient of the 10-Q filing
• June 30, 2025 (date) — end of the quarterly reporting period
• August 11, 2025 (date) — filing date of the 10-Q
• Utah (location) — state of incorporation for Nu-Med Plus, Inc.
• Port Jefferson, NY (location) — business address of Nu-Med Plus, Inc.
• 000-54808 (identifier) — Commission File Number for Nu-Med Plus, Inc.
• 3841 (identifier) — Standard Industrial Classification (SIC) code for Surgical & Medical Instruments & Apparatus

FAQ

Risk Factors

• Lack of Revenue Generation [high — financial]: Nu-Med Plus, Inc. reported $0 in revenue for the quarter ended June 30, 2025. As a development-stage company, it faces significant challenges in bringing medical devices to market, which requires substantial capital investment and time.
• Medical Device Approval Process [high — regulatory]: The company operates in the medical device industry, which is subject to stringent regulatory approvals from bodies like the FDA. Delays or failures in obtaining these approvals can significantly impact the company's ability to generate revenue and achieve commercial success.
• Development Stage Operations [medium — operational]: As a development-stage company, Nu-Med Plus is still in the process of developing its products. This phase is characterized by high uncertainty, ongoing research and development costs, and a lack of established operational history or market traction.
• Capital Requirements [high — financial]: Bringing medical devices to market is capital-intensive, requiring significant funding for research, development, clinical trials, manufacturing, and regulatory compliance. The company's ability to secure ongoing financing is critical for its survival and progress.

Industry Context

Nu-Med Plus, Inc. operates within the Surgical & Medical Instruments & Apparatus industry (SIC 3841). This sector is characterized by innovation, significant R&D investment, and a highly regulated environment. Companies in this space face intense competition from established players and emerging startups, with success often hinging on technological breakthroughs and successful navigation of regulatory pathways.

Regulatory Implications

As a medical device company, Nu-Med Plus is subject to rigorous oversight by regulatory bodies such as the FDA. The process of obtaining approvals for new medical devices is lengthy, costly, and uncertain, posing a significant risk to the company's ability to commercialize its technology and generate revenue.

What Investors Should Do

1. Monitor R&D progress and regulatory milestones.
2. Assess cash burn rate and future financing needs.
3. Evaluate the competitive landscape and market adoption potential.

Key Dates

• 2025-06-30: Quarterly Period End — Marks the end of the financial reporting period for the 10-Q filing.
• 2025-08-11: 10-Q Filing Date — Official date the company submitted its quarterly report to the SEC, providing updated financial and operational information.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a continuing disclosure by public companies. (This is the form Nu-Med Plus, Inc. filed, detailing its financial performance and operational status for the quarter.)

Development-stage company

A company that has not yet established a regular revenue stream and is primarily focused on research and development or bringing a product to market. (Explains why Nu-Med Plus, Inc. has zero revenue and is still incurring costs without generating income.)

Smaller reporting company

A company that meets certain criteria regarding public float and annual revenue, allowing for scaled disclosure requirements. (Indicates Nu-Med Plus, Inc.'s limited financial scale and market capitalization.)

Non-accelerated filer

A type of filer that is not a large accelerated filer or an accelerated filer, typically indicating a smaller company with less frequent reporting obligations. (Further emphasizes the company's smaller size and reduced reporting burden compared to larger corporations.)

SIC Code 3841

Standard Industrial Classification code for Surgical and Medical Instruments and Apparatus. (Classifies Nu-Med Plus, Inc.'s core business focus within the medical technology sector.)

Year-Over-Year Comparison

This filing indicates Nu-Med Plus, Inc. continues to operate as a development-stage company with no revenue for the quarter ended June 30, 2025, consistent with its prior status. No specific comparative financial metrics like revenue growth or margin changes can be assessed as revenue remains at $0. The company's classification as a smaller reporting company and non-accelerated filer also remains unchanged, suggesting no significant shift in its financial scale or reporting requirements.

Key Financial Figures

• $0.001 — August 11, 2025. 83,548,469 shares of $0.001 par value common stock on August 11, 20

Filing Documents

• numd-20250630.htm.htm (10-Q) — 256KB
• ex31-1.htm (EX-31) — 7KB
• ex31-2.htm (EX-31) — 8KB
• ex32.htm (EX-32) — 4KB
• 0001548123-25-000047.txt ( ) — 1890KB
• numd-20250630.xsd (EX-101.SCH) — 15KB
• numd-20250630_cal.xml (EX-101.CAL) — 16KB
• numd-20250630_def.xml (EX-101.DEF) — 69KB
• numd-20250630_lab.xml (EX-101.LAB) — 137KB
• numd-20250630_pre.xml (EX-101.PRE) — 79KB
• numd-20250630.htm_htm.xml (XML) — 102KB

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 5 ITEM 2 MANAGEMENT'S DISCUSSION AND ANAYLSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 14 ITEM 3

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 18 ITEM 4

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 18 PART II OTHER INFORMATION 19 ITEM 1

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 19 ITEM 1A

RISK FACTORS

RISK FACTORS 19 ITEM 1C CYBERSECURITY 19 ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 20 ITEM 3 DEFAULTS UPON SENIOR SECURITIES 20 ITEM 4 MINE SAFETY DISCLOSURE 20 ITEM 5 OTHER INFORMATION 20 ITEM 6 EXHIBITS 20

- FINANCIAL INFORMATION

Part I - FINANCIAL INFORMATION

Financial

Item 1. Financial NU-MED PLUS, INC.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS (UNAUDITED) June 30, 2025 The financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. However, in the opinion of management, all adjustments (which include only normal recurring accruals) necessary to present fairly the financial position and results of operations for the periods presented have been made. These financial statements should be read in conjunction with the Form 10-K for the period ended December 31, 2024, accompanying notes, and with the historical financial information of the Company. The results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the results to be expected for the year ending December 31, 2025. 4 Nu-Med Plus, Inc.

Financial Statements

Financial Statements Table of Contents Page No. Condensed Balance Sheets at June 30, 2025 (unaudited) and December 31, 2024 6 Condensed Statements of Operations for the three and six months ended June 30, 2025 and 2024 (unaudited) 7 Condensed Statements of Stockholders' Deficit for the three and six months ended June 30, 2025 and 2024 (unaudited) 8 Condensed Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (unaudited) 9 Notes to the Condensed Financial Statements (unaudited) 10 5 NU-MED PLUS, INC. Condensed Balance Sheets June 30, December 31, 2025 (unaudited) 2024 ASSETS Current assets Cash $ 863 $ 2,373 Prepaid expenses 7,300 7,000 Total current assets 8,163 9,373 Total assets $ 8,163 $ 9,373 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable $ 55,204 $ 43,040 Accounts payable – related party 86,160 66,710 Note payable 100,000 100,000 Accrued expenses 13,493 14,719 Total current liabilities 254,857 224,469 Long-term liabilities - - Total liabilities 254,857 224,469 Commitments and contingencies - - Stockholders' deficit Preferred stock; $ 0.001 par value; 10,000,000 authorized; no shares issued and outstanding - - Common stock; $ 0.001 par value; 90,000,000 authorized; 83,548,469 and 83,548,469 shares issued and outstanding, as of June 30, 2025 and December 31, 2024, respectively. 83,549 83,549 Additional paid-in capital 9,594,687 9,594,687 Accumulated deficit ( 9,924,930 ) ( 9,893,332 ) Total stockholders' deficit ( 246,694 ) ( 215,096 ) Total liabilities and stockholders' deficit $ 8,163 $ 9,373 The accompanying notes are an integral part of these condensed financial statements. 6 NU-MED PLUS, INC. Condensed Statements of Operations (Unaudited) Three months ended June 30, 2025 Three months ended June 30, 2024 Six months ended June 30, 2025 Six months ended June 3

Management's

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Special Note Regarding Forward-Looking Statements Certain statements in this Report constitute "forward-looking actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, among others, uncertainties relating to general economic and business conditions; industry trends; changes in demand for our products and services; uncertainties relating to customer plans and commitments and the timing of orders received from customers; announcements or changes in our pricing policies or that of our competitors; unanticipated delays in the development, market acceptance or installation of our products and services; changes in government regulations; availability of management and other key personnel; availability, terms and deployment of capital; relationships with third-party equipment suppliers; and worldwide political stability and economic growth. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. Critical Accounting Policies and Estimates The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circum

Business

Business The mission of NU-MED is to design, develop, and market technologies in the medical device field. Our technologies will focus on market niches in high growth trend areas. We hope each developed technology will fill a current need in medical procedures by improving upon an existing technology or device, or by designing a device to serve a need that is clearly defined and acknowledged by medical professionals. NU-MED is a medical device company principally engaged in the design, innovation, development, enhancement and commercialization of beginning, early, and selective later-stage quality medical devices. The mission of NU-MED is to design, develop, and market technologies utilizing nitric oxide in the medical device field. Our technologies focus on market niches in high growth trend areas. Our products are developed to target a current need in medical procedures by improving upon an existing technology or device or by designing a device to serve a currently unfilled need that is clearly defined and acknowledged by medical professionals. Our focus has been on the creation of a nitric oxide generating formulation, a hospital bedside nitric oxide delivery system, a clinical unit for use in medical clinics and rehabilitation centers and a mobile device to deliver nitric oxide gas to offer new and innovative solutions to hospitals, health systems and the medical community throughout the world. Development of our products has been suspended until such time as a capital infusion is received which will enable the funding of further development. The following is a description of the medical application for the products that have been under development and the status of each of those products: Nitric oxide is an extremely important bio-mediator in the human body that is produced from the amino acid l-arginine. Nitric oxide has anti-inflammatory properties, antibacterial, antiviral and antifungal properties which make it useful in certain medical treatments. At

View Full Filing

View this 10-Q filing on SEC EDGAR